| 注册
首页|期刊导航|癌症生物学与医学(英文版)|Immunotherapy rechallenge of patients with advanced NSCLC progression after sequential treatment with third-generation EGFR-TKI and immunotherapy

Immunotherapy rechallenge of patients with advanced NSCLC progression after sequential treatment with third-generation EGFR-TKI and immunotherapy

Shuyi Hu Ying Liu Tianyi Liu Lin Lu Chengyun Yao Bo Shen Meiqi Shi Cheng Chen Xiaohua Wang Guoren Zhou Zipeng Wu Yingying Dai Xinhong Shi Qin Hu Caolu Liu Yifei Zhu Ruofan Yu Jingwen Li

癌症生物学与医学(英文版)2025,Vol.22Issue(12):1544-1552,9.
癌症生物学与医学(英文版)2025,Vol.22Issue(12):1544-1552,9.DOI:10.20892/j.issn.2095-3941.2025.0393

Immunotherapy rechallenge of patients with advanced NSCLC progression after sequential treatment with third-generation EGFR-TKI and immunotherapy

Immunotherapy rechallenge of patients with advanced NSCLC progression after sequential treatment with third-generation EGFR-TKI and immunotherapy

Shuyi Hu 1Ying Liu 1Tianyi Liu 2Lin Lu 2Chengyun Yao 2Bo Shen 1Meiqi Shi 1Cheng Chen 3Xiaohua Wang 1Guoren Zhou 1Zipeng Wu 1Yingying Dai 2Xinhong Shi 1Qin Hu 1Caolu Liu 2Yifei Zhu 1Ruofan Yu 1Jingwen Li1

作者信息

  • 1. Department of Oncology,The Affiliated Cancer Hospital of Nanjing Medical University,Jiangsu Cancer Hospital,Jiangsu Institute of Cancer Research,Nanjing 210009,China
  • 2. Department of Radiotherapy,The Affiliated Cancer Hospital of Nanjing Medical University,Jiangsu Cancer Hospital,Jiangsu Institute of Cancer Research,Nanjing 210009,China
  • 3. Department of Radiotherapy,The Affiliated Cancer Hospital of Nanjing Medical University,Jiangsu Cancer Hospital,Jiangsu Institute of Cancer Research,Nanjing 210009,China||Peking University Cancer Hospital(Inner Mongolia Campus),Affiliated Cancer Hospital of Inner Mongolia Medical University,Hohhot 010020,China
  • 折叠

摘要

引用本文复制引用

Shuyi Hu,Ying Liu,Tianyi Liu,Lin Lu,Chengyun Yao,Bo Shen,Meiqi Shi,Cheng Chen,Xiaohua Wang,Guoren Zhou,Zipeng Wu,Yingying Dai,Xinhong Shi,Qin Hu,Caolu Liu,Yifei Zhu,Ruofan Yu,Jingwen Li..Immunotherapy rechallenge of patients with advanced NSCLC progression after sequential treatment with third-generation EGFR-TKI and immunotherapy[J].癌症生物学与医学(英文版),2025,22(12):1544-1552,9.

基金项目

This work was supported by grants from the National Natural Science Foundation of China(Grant No.82273162)and Jiangsu Cancer Hospital Science and Technology Development Fund Project(Grant No.YSZD202409). (Grant No.82273162)

癌症生物学与医学(英文版)

2095-3941

访问量0
|
下载量0
段落导航相关论文